secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001493152-23-029156
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma Q2 net loss $4.2M; cash $32.4M; advances antiviral pipeline
----------------------------------------------------------------------------

- Net loss $4.2M ($0.41/share) vs $24.4M ($3.00) in Q2 2022, which included $19.1M goodwill impairment and legal settlement.
- Cash $32.4M at June 30, 2023 vs $37.1M at Dec 31, 2022; management expects sufficient for 12 months.
- On track to initiate Phase 2a trial for CC-42344 (influenza A) in H2 2023 pending UK MHRA clearance.
- Selected novel protease inhibitor CDI-988 as lead oral norovirus candidate; Phase 1 cleared by Australian regulator.
- Completed $4.0M private placement of common stock with directors Fred Hassan and Phillip Frost.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/0001493152-23-029156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223029156/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer